Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Tuesday's Featured Content Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after recent market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best periods in history to build wealth—if you think long-term and stick to time-tested principles. According to Green, the pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling pressure has more to do with valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back Your $200 MarketBeat account credit expires in less than twelve hours. Upgrade to MarketBeat All Access today and save $200 on your 2025-2026 MarketBeat premium subscription. Claim My Discount Green attributes the dip to two core concerns. First, investors are starting to question elevated tech and AI valuations, especially as earnings season brings those expectations into focus. Second, inflation readings and softer hiring have dimmed hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" posture, markets are less certain that relief is coming this year. Why Selling Now Might Be the Wrong Move Rather than trying to predict next week's moves, Green encourages investors to zoom out. He calls himself "a long-term optimist" and points out that, historically, the market's trend is upward. Traders may want to exercise short-term caution. But for long-term investors, these dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable indicator in times like these is insider buying. Green notes that when company officers and directors—people with access to non-public financial information—are putting money into their own firms, it's worth paying attention to. He recommends tracking insider trading activity to see which stocks executives are buying, not just selling. While insiders aren't always right, their actions can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a single blood draw. Green has used the test himself and says it feels reassuring to know you're clear of so many deadly diseases—especially ones like pancreatic cancer that often go undetected until late stages. With FDA fast-track status and potential for insurance reimbursement ahead, Green views GRAIL's roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech carries real risk—most drugs never make it through all phases of trials. Still, large pharmaceutical companies like Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) frequently acquire promising small caps to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example: the company invested in a private prostate-cancer drug before FDA approval—underscoring how aggressive Big Pharma can be when clinical trials look promising. He believes biotech is especially compelling now because healthcare is recession-resistant. Whether the economy is growing or shrinking, people still need treatment. For investors seeking stability through volatility, sectors like healthcare, utilities, consumer staples, and food companies tend to offer steady demand—and less drama than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream is far from dead. He wrote The American Dream to counter the narrative that it's out of reach, noting he was surprised to find nearly 70% of Americans think it's no longer attainable. The reality, he says, is that with low-cost investment tools, no-commission trading, and widely available information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to do it. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save and leave that money to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says it doesn't have to be. Mortgage rates have doubled and prices are up about 50% since the pandemic—but there are still ways in. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method often called a "contract for deed." It might not land you the perfect house immediately, but it can help you start building equity sooner than you think. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside sectors like biotech, or simply believing in your ability to build a financial future, Green's message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
